Scancell (LON:SCLP) Shares Pass Above Fifty Day Moving Average – Should You Sell?

Scancell Holdings plc (LON:SCLP)’s stock price crossed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of GBX 9.68 ($0.13) and traded as high as GBX 10 ($0.13). Scancell shares last traded at GBX 9.80 ($0.13), with a volume of 2,029,318 shares changing hands.

Scancell Stock Up 0.5%

The company has a 50-day moving average price of GBX 9.68 and a 200 day moving average price of GBX 9.95. The firm has a market capitalization of £101.70 million, a PE ratio of -7.78 and a beta of 0.35. The company has a debt-to-equity ratio of -566.79, a current ratio of 3.42 and a quick ratio of 13.01.

Scancell (LON:SCLP) last announced its quarterly earnings data on Thursday, September 11th. The company reported GBX (1.26) EPS for the quarter. Analysts forecast that Scancell Holdings plc will post -2.5361112 earnings per share for the current year.

Insider Activity at Scancell

In other Scancell news, insider Martin Diggle acquired 4,400,000 shares of the stock in a transaction dated Friday, August 1st. The shares were acquired at an average cost of GBX 10 per share, for a total transaction of £440,000. Insiders bought 7,652,236 shares of company stock valued at $73,474,596 in the last quarter. 15.45% of the stock is owned by insiders.

Scancell Company Profile

Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma.